Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
gene therapy
PTC THERAPEUTICS, INC.
Aromatic L-amino Acid Decarboxylase (AADC) Deficiency
1 trial -
A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma
KYOWA KIRIN AUSTRALIA PTY LTD
T-cell Non-Hodgkin Lymphoma, Cutaneous T-cell lymphoma (CTCL), Peripheral T-cell lymphoma (PTCL)
1 trial -
A study to learn about the study medicine called PF-08046032 in people with advanced cancers.
Pfizer Australia Pty Ltd
Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell lymphoma [PTCL], and diffuse large B cell lymphoma [DLBCL]), Solid tumors (eg, NSCLC, HNSCC, and melanoma)
1 trial -
An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma
BioNTech SE
Metastatic melanoma
1 trial -
Ataluren
PTC THERAPEUTICS, INC.
Healthy
1 trial -
Deflazacort
PTC THERAPEUTICS, INC.
Hepatic Impairment
1 trial -
Deflazacort
PTC THERAPEUTICS, INC.
Renal Impairment
1 trial -
Deflazacort
PTC THERAPEUTICS, INC.
Healthy Volunteers
1 trial -
Deflazacort and rifampin
PTC THERAPEUTICS, INC.
Healthy Volunteers
1 trial -
PTC299
PTC THERAPEUTICS, INC.
Metastatic Breast Cancer
1 trial -
PTC299
PTC THERAPEUTICS, INC.
Leukemia, Myeloid, Acute
1 trial -
PTC299
PTC THERAPEUTICS, INC.
Advanced Cancer
1 trial -
PTC596
PTC THERAPEUTICS, INC.
High Grade Glioma
1 trial -
PTC596
PTC THERAPEUTICS, INC.
Cancer
1 trial -
Unesbulin
PTC THERAPEUTICS, INC.
Ovarian Cancer
1 trial -
VEGF inhibitor PTC299
PTC THERAPEUTICS, INC.
Brain and Central Nervous System Tumors
1 trial -
Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Istituto Gentili S.r.l.
Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.
1 trial -
A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).
The First People's Hospital of Lianyungang
Neuromuscular Blockade
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources